María Gómez‐Cañas

Author

María Gómez‐Cañas

Biomedical Research Networking Center on Neurodegenerative Diseases ORCID

Also Known As

M. Gómez-Cañas, Maria Gomez-Canas, Maria Gómez-Cañas, Maria Gómez‐Cañas, María Goméz-Cañas, María Gómez-Cañas, María Gómez‐Cañas

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Biomedical Research Networking Center on Neurodegenerative Diseases Universidad Complutense de Madrid Instituto Ramón y Cajal de Investigación Sanitaria University of Córdoba Instituto de Química Médica

About

María Gómez‐Cañas is an author at Biomedical Research Networking Center on Neurodegenerative Diseases specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	17	669
2	Biochemistry	6	6	129
3	Natural Sciences	3	3	76
4	Social Sciences	2	2	47
5	Health Sciences	1	1	50

María Gómez‐Cañas

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis Aitor G. Granja, Francisco J. Carrillo‐Salinas, Alberto Pagani, Journal of Neuroimmune Pharmacology Neurological DisorderMedicineNeuropharmacologyChronic ModelNeuroprotection	2012	154
Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB <sub>1</sub> receptors on developing cortical neurons Adán de Salas-Quiroga, Javier Díaz-Alonso, Daniel García-Rincón, Proceedings of the National Academy of Sciences	2015	152
Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling Estefanía Moreno, Clara Andradas, Mireia Medrano, Journal of Biological Chemistry Functional SelectivityMedicineCancer Cell BiologyCancer BiologyRadiation Oncology	2014	113
The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways Carmen del Río, Carmen Navarrete, Juan A. Collado, Scientific Reports	2016	90
Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor Concepción García, María Gómez‐Cañas, Sonia Burgaz, Journal of Neuroinflammation	2018	62
Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease Pedro González-Naranjo, Natalia Pérez-Macías, Nuria E. Campillo, European Journal of Medicinal Chemistry Cannabis UsePsychoactive DrugAlzheimer's DiseaseBuche InhibitionPotential Therapeutic Agents	2013	50
Synthetic cannabinoid quinones: Preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity Paula Morales, Diana Vara‐Ciruelos, María Gómez‐Cañas, European Journal of Medicinal Chemistry Cannabis UseMedicinal ChemistryVitro Antiproliferative EffectsMedicineCannabis Legalization	2013	46
Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis Paula Morales, María Gómez‐Cañas, Gemma Navarro, Journal of Medicinal Chemistry ImmunologyMedicinal ChemistryCannabinoid Binding AssaysNeurologyChromenopyrazole Ring	2016	45
Selective, Nontoxic CB<sub>2</sub> Cannabinoid <i>o</i>-Quinone with in Vivo Activity against Triple-Negative Breast Cancer Paula Morales, Sandra Blasco-Benito, Clara Andradas, Journal of Medicinal Chemistry Cannabis UseMedicinal ChemistryVivo ActivityDual Concept Quinone/cannabinoidMedicine	2015	38
<scp>VCE</scp>‐004.3, a cannabidiol aminoquinone derivative, prevents bleomycin‐induced skin fibrosis and inflammation through PPARγ‐ and CB<sub>2</sub> receptor‐dependent pathways Carmen del Río, Irene Cantarero, Belén Palomares, British Journal of Pharmacology	2018	38

Page 1